Mangalam Drugs and Organics Ltd

₹ 30.3 1.98%

08 May - close price

mangalamdrugs.com BSE: 532637 NSE: MANGALAM

About

Incorporated in 1977, Mangalam Drugs & Organics Ltd manufactures Active Pharmaceutical Ingredients and Intermediates.^[1]

Key Points

Business Overview:^[1]
MDOL (formerly Advent Pharma Pvt Ltd) is a part of the Mangalam group. The co manufactures bulk drugs, and organic and inorganic chemicals. It is among the few companies which are World Health Org.approved Indian companies to be associated
with the William J Clinton Foundation (Clinton Foundation) for manufacture of anti-malarial drugs. MDOL supplies artemisinin-based bulk drugs to pharmaceutical companies, for the manufacture of anti-malarial formulations.

Website BSE NSE - BE

Market Cap ₹ 48.0 Cr.
Current Price ₹ 30.3
High / Low ₹ 95.0 / 22.7
Stock P/E
Book Value ₹ 80.6
Dividend Yield 0.00 %
ROCE 8.05 %
ROE 4.68 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Stock is trading at 0.38 times its book value

Cons

Company has low interest coverage ratio.
Promoter holding is low: 35.6%
Contingent liabilities of Rs.34.6 Cr.
Debtor days have increased from 36.2 to 44.8 days.
Promoter holding has decreased over last 3 years: -14.7%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
	97.34	102.24	76.53	79.94	88.71	73.04	57.35	49.54	58.49
	90.36	90.55	68.34	71.24	79.94	62.88	61.83	52.38	59.92
Operating Profit	6.98	11.69	8.19	8.70	8.77	10.16	-4.48	-2.84	-1.43
OPM %	7.17%	11.43%	10.70%	10.88%	9.89%	13.91%	-7.81%	-5.73%	-2.44%
	0.00	0.05	0.02	0.14	0.14	0.21	0.00	0.03	0.11
Interest	3.31	3.95	3.75	3.67	3.49	4.03	4.04	5.03	4.05
Depreciation	3.63	3.86	3.88	3.97	4.05	4.70	4.48	4.63	4.46
Profit before tax	0.04	3.93	0.58	1.20	1.37	1.64	-13.00	-12.47	-9.83
Tax %	-1,150.00%	10.18%	-362.07%	-124.17%	5.84%	95.73%	6.15%	-41.06%	0.00%
	0.50	3.53	2.68	2.69	1.29	0.06	-13.80	-7.35	-9.84
EPS in Rs	0.32	2.23	1.69	1.70	0.82	0.04	-8.72	-4.64	-6.22
Raw PDF

Upcoming result date: 14 May 2026

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2024	Mar 2025	TTM
	369	318	238
	351	282	237
Operating Profit	17	36	1
OPM %	5%	11%	1%
	0	0	0
Interest	14	15	17
Depreciation	15	17	18
Profit before tax	-11	5	-34
Tax %	-18%	-41%
	-9	7	-31
EPS in Rs	-5.73	4.25	-19.54
Dividend Payout %	0%	0%

Compounded Sales Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	-31%

Compounded Profit Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	-404%

Stock Price CAGR
10 Years:	-18%
5 Years:	-26%
3 Years:	-35%
1 Year:	-58%

Return on Equity
10 Years:	%
5 Years:	%
3 Years:	%
Last Year:	5%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2024	Mar 2025	Sep 2025
Equity Capital	16	16	16
Reserves	120	133	112
	107	96	95
	91	121	94
Total Liabilities	334	366	317
	148	163	159
CWIP	8	3	4
Investments	0	0	0
	178	201	155
Total Assets	334	366	317

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2024	Mar 2025
	4	43
	-12	-19
	5	-22
Net Cash Flow	-3	1
Free Cash Flow	-8	23
CFO/OP	23%	118%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2024	Mar 2025
Debtor Days	28	45
Inventory Days	185	303
Days Payable	99	199
Cash Conversion Cycle	113	149
Working Capital Days	11	5
ROCE %		8%

Insights

In beta

Mar 2014

Mar 2015

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Research & Development Spend
INR Lakhs ・Standalone data

xx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	x.xx	xxx.xx	xxx.xx	x,xxx.xx
		xx,xxx.xx	xx,xxx.xx	xx,xxx.xx	xx,xxx.xx	xx,xxx.xx	xx,xxx.xx	xx,xxx.xx	xx,xxx.xx	xx,xxx.xx	xx,xxx.xx
	xxx		xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx
		x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	xx,xxx.xx	xx,xxx.xx	xx,xxx.xx	xx,xxx.xx
		x		x	x			xx		xx
		xx		xx	xx
		x,xxx	xxx

Please log in to see hidden values.

Sale of Products (API/Intermediates)
INR Lakhs ・Standalone data

Total Number of Employees
Count ・Standalone data

Export Turnover
INR Lakhs ・Standalone data

Number of WHO Approved DMFs
Count ・Standalone data

Number of Research Scientists
Count ・Standalone data

Manufacturing Capacity - APIs
TPA ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	50.31%	50.31%	50.31%	50.31%	50.31%	50.30%	50.30%	50.30%	50.30%	50.30%	35.64%	35.65%
	0.10%	0.10%	0.10%	0.26%	0.21%	0.11%	0.11%	0.47%	0.53%	0.11%	0.13%	0.32%
	49.58%	49.59%	49.59%	49.42%	49.47%	49.58%	49.58%	49.23%	49.16%	49.57%	64.22%	64.03%
No. of Shareholders	17,890	17,978	18,610	19,173	19,312	19,508	19,679	19,697	19,728	19,881	21,227	25,140

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	50.76%	50.76%	49.27%	50.53%	50.53%	50.53%	50.31%	50.31%	50.30%	35.65%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.10%	0.10%	0.26%	0.47%	0.32%
	0.19%	0.25%	1.29%	0.01%	0.01%	0.01%	0.00%	0.00%	0.00%	0.00%
	49.05%	48.99%	49.44%	49.46%	49.46%	49.36%	49.59%	49.42%	49.23%	64.03%
No. of Shareholders	15,529	18,113	19,611	17,884	20,520	20,084	17,943	19,173	19,697	25,140

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Mangalam Drugs and Organics Ltd

Mangalam Drugs and Organics Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Insights

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls